Comparable stake leader
Timothy Mark Dyer
SEC ownership of Addex Therapeutics Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001574232.
Disclosed value leader
Timothy Mark Dyer
Comparable rows
5/11
Latest evidence
31 Mar 2026
- Public ticker
- ADXN on Nasdaq
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Timothy Mark Dyer
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
5 of 11
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Timothy Mark Dyer
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001574232
- Issuer location
- Geneva, Switzerland
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Addex Therapeutics Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Timothy Mark Dyer
Disclosed value leader
Timothy Mark Dyer
Comparable rows
5/11
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 13%
6 rows are not safely comparable across share classes.
13D/G row: Timothy Mark Dyer
Showing 1-8 of 11 holder rows.
Quick read
Timothy Mark Dyer leads the comparable SEC ownership view at 13%.
5 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Timothy Mark Dyer's linked filing trail.
Comparable ownership
Top 5
Timothy Mark Dyer
13%
MORGAN STANLEY
0%
GAMMA Investing LLC
0%
RHUMBLINE ADVISERS
0%
SBI Securities Co., Ltd.
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Timothy Mark Dyer |
13D/G
3/4/5
Chief Executive Officer, Director, 10%+ Owner
|
13%
|
$153,679,208
18,208,437 shares
|
$0 | 20 Jun 2025 |
| MORGAN STANLEY |
13F
Company
|
0%
|
$1,893
301 shares
|
— | 31 Mar 2026 |
| GAMMA Investing LLC |
13F
Company
|
0%
|
$509
81 shares
|
— | 31 Mar 2026 |
| RHUMBLINE ADVISERS |
13F
Company
|
0%
|
$450
72 shares
|
— | 31 Mar 2026 |
| SBI Securities Co., Ltd. |
13F
Company
|
0%
|
$6
1 shares
|
— | 31 Mar 2026 |
| Vincent Michael Lawton |
3/4/5
Director
|
—
class O/S missing
|
—
2,507,987 shares
|
— | 18 Mar 2026 |
| Raymond George Hill |
3/4/5
Director
|
—
class O/S missing
|
—
1,365,532 shares
|
— | 18 Mar 2026 |
| Roger Mills |
3/4/5
CHIEF MEDICAL OFFICER, Director
|
—
class O/S missing
|
—
785,976 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-8 of 8 reporting-owner rows connected to Addex Therapeutics Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
8
Largest Forms 3/4/5 holder
Isaac Manke
Net 12M change
$0
Latest report
18 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Isaac Manke | Director | Mixed | 18 Mar 2026 | |||
| Jason R. Nunn | Director | Mixed | 18 Mar 2026 | |||
| Timothy Mark Dyer | Chief Executive Officer, Director, 10%+ Owner | Mixed | 18 Mar 2026 | |||
| Raymond George Hill | Director | Mixed | 18 Mar 2026 | |||
| Mikhail Kalinichev | Head Of Translational Science | Mixed | 18 Mar 2026 | |||
| Lenaic Nathanael Teyssedou | Principal Accounting Officer | Mixed | 18 Mar 2026 | |||
| Vincent Michael Lawton | Director | Mixed | 18 Mar 2026 | |||
| Roger Mills | CHIEF MEDICAL OFFICER, Director | Mixed | 18 Mar 2026 |
Recent insider transactions for Addex Therapeutics Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Roger Mills | ADXN | Common Stock | 0 | 785,976 | 18 Mar 2026 | Direct | ||||
| Vincent Michael Lawton | ADXN | Common Stock | 0 | 2,507,987 | 18 Mar 2026 | Direct | ||||
| Mikhail Kalinichev | ADXN | Common Stock | 0 | 306,765 | 18 Mar 2026 | Direct | ||||
| Raymond George Hill | ADXN | Common stock | 0 | 1,365,532 | 18 Mar 2026 | Direct | ||||
| Timothy Mark Dyer | ADXN | Common stock | 0 | 16,848,979 | 18 Mar 2026 | Direct | ||||
| Jason Raleigh Nunn | ADXN | Common Stock | 0 | 219,561 | 18 Mar 2026 | Direct | ||||
| Isaac Manke | ADXN | Common Stock | 0 | 219,561 | 18 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.